As the ILAE 2013 system is based on a qualitative assessment of overall NeuN labeling rather than actual neuronal cell counts, we hypothesized that MAP2 could provide a more sensitive qualitative evaluation in these indeterminate HS cases. This evidence concerns the gene RBFOX3 and histiocytic sarcoma.